IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
JFL Life Sciences IPO is a Fixed Price listing on NSE EMERGE exchange. The company is based in Ahmedabad and caters to Pharmaceutical sector. GYR Capital Advisors is the merchant banker of JFL Life Sciences IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 12th April 2022.
JFL Life Sciences IPO posted revenues of ₹ 27.96 crores and PAT of ₹ 2.76 crores in FY22 on annualised basis.
Revenue:
₹ 27.17 Cr.
EBITDA Margin:
19.71
% 
Net Worth: ₹ 10.97 Cr.
Market Capitalisation:
₹ 67.09 Cr.
P/E:
26.52 times
P/BV: 2.30 times
EV/EBITDA: 15.45 times
Financial results of JFL Life Sciences IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Feb-22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 36.63 | 29.01 | 24.33 | 16.15 | |
| Net Worth | 10.97 | 6.87 | 5.37 | 5.01 | |
| Total Debt | 16.00 | 16.82 | 9.32 | 8.40 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
24.91
27.17 |
32.77 | 30.17 | 31.78 | |
EBITDA
EBITDA on annualised basis |
4.91
5.36 |
1.98 | 1.66 | 1.17 | |
PAT
PAT on annualised basis |
2.53
2.76 |
0.54 | 0.36 | 0.30 | |
JFL Life Sciences IPO PAT Margin is 10.16 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows JFL Life Sciences IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Feb-22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|
| EBITDA Margin (%) | 19.71 | 6.04 | 5.50 | 3.68 |
| PAT Margin (%) | 10.16 | 1.65 | 1.19 | 0.94 |
| EPS (₹) | 3.77 | 0.89 | 0.66 | 0.59 |
| ROE (%) | 23.06 | 7.86 | 6.70 | 5.99 |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 6.91 | 1.86 | 1.48 | 1.86 |
| Debt to Equity | 1.46 | 2.45 | 1.74 | 1.68 |
The market Capitalisation of JFL Life Sciences IPO is ₹ 67.09 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The JFL Life Sciences IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows JFL Life Sciences IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of JFL Life Sciences IPO is ₹ 67.09 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The JFL Life Sciences IPO has a Price-to-Earnings (PE) ratio of 26.52 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
JFL Life Sciences IPO reported revenue of ₹ 27.96 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from JFL Life Sciences IPO provide insights into sales growth, market demand, and business scalability.
JFL Life Sciences recorded an EBITDA of ₹ 5.36 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
JFL Life Sciences Profit After Tax (PAT) is ₹ 2.76 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 27.17 Cr.
EBITDA Margin:
19.71
%
Net Worth: ₹ 10.97 Cr.
Market Capitalisation:
₹ 67.09 Cr.
P/E:
26.52 times
P/BV: 2.30 times
EV/EBITDA: 15.45 times
JFL Life Sciences operates in Pharmaceutical and Manufacturing Of Pharmaceutical Products. The Issue is listed on NSE EMERGE in Sep, 2022. JFL Life Sciences IPO size was 18.17 with Issue price of 61.00 .
Merchant Banker(s) of JFL Life Sciences IPO: GYR Capital Advisors Private Limited
JFL Life Sciences IPO subscription was 8.93 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
JFL Life Sciences IPO listed at a listing price of 66.50 against the offer price of 61.00.
The current market price of JFL Life Sciences is 18.75.
Why Us?
